Pdl Biopharma Inc (PDLI)

Pdl Biopharma Inc (PDLI)

Indicator:

BOLLINGER BANDS

BULLISH CROSSUNDER

Indicator is best used in conjunction with additional indicators as it has the ability to highlight potential overbought or oversold levels. This indicator utilizes upper and lower bands to visually represent price extremes associated with the bands. Additional value can be added to the trading strategy by accessing divergences between price and volume.

Pdl Biopharma Inc (NASDAQ:PDLI) is no longer overbought The current level is 122.91% with a current width of 12.18.

The purpose of the Bollinger Bands is to provide a relative definition of high and low. By definition prices are high at the upper band and low at the lower band. This definition can aid in rigorous pattern recognition and is useful in comparing price action of the action of indicators to arrive at systematic trading decision.

Calculation: Bollinger Bands:
1) Middle Band = 20-day simple moving average (SMA);
2) Upper Band = 20-day SMA + (20-day standard deviation of price x 2);
3) Lower Band = 20-day SMA - (20-day standard deviation of price x 2);

PROFILE: Pdl Biopharma Inc (PDLI)

Stock Exchange: NASDAQ
Company: Pdl Biopharma Inc
Ticker Codes: | PDLI | NASDAQ:PDLI |

PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates in three segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Medical Devices segment manufactures and sells LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.